Special Articles

You have full text access to this OnlineOpen article

Prevention of acute adverse events related to infliximab infusions in pediatric patients

  1. P. Lahdenne*,
  2. A. M. Wikström,
  3. K. Aalto,
  4. K. L. Kolho

Article first published online: 1 JUN 2010

DOI: 10.1002/acr.20246

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 62, Issue 6, pages 785–790, June 2010

Additional Information

How to Cite

Lahdenne, P., Wikström, A. M., Aalto, K. and Kolho, K. L. (2010), Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res, 62: 785–790. doi: 10.1002/acr.20246

Author Information

  1. Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland

*Hospital for Children and Adolescents, University of Helsinki, Box 281, FIN-00029 HUS, Finland

Publication History

  1. Issue published online: 1 JUN 2010
  2. Article first published online: 1 JUN 2010
  3. Manuscript Accepted: 2 NOV 2009
  4. Manuscript Received: 7 JUL 2009

Funded by

  • Foundation for Pediatric Research, Finland
  • Päivikki and Sakari Sohlberg Foundation, Finland

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (72K)

REFERENCES

  • 1
    Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003; 62: 245–7.
  • 2
    Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56: 3096–106.
    Direct Link:
  • 3
    Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor necrosis factor-α blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007; 34: 1146–50.
  • 4
    Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 548–50.
  • 5
    Lamireau T, Cezard JP, Dabadie A, Goulet O, Lachaux A, Turck D, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004; 10: 745–50.
    Direct Link:
  • 6
    Ruemmele FM, Lachaux A, Cezard JP, Morali A, Maurage C, Ginies JL, et al. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 2009; 15: 388–94.
    Direct Link:
  • 7
    Tynjala P, Vahasalo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of anti-TNF agents in juvenile idiopathic arthritis. Ann Rheum Dis 2009; 68: 552–7.
  • 8
    D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007; 56: 725–32.
  • 9
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275–85.
  • 10
    Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatrica 2007; 96: 128–30.
    Direct Link:
  • 11
    Ebert EC, Das KM, Mehta V, Rezac C. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-α antibodies. Clin Exp Immunol 2008; 154: 325–31
    Direct Link:
  • 12
    Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315–24.
    Direct Link:
  • 13
    Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory disease center. Am J Gastroenterol 2003; 98: 104–11.
    Direct Link:
  • 14
    Jacobstein DA, Markowitz JE, Kirschner BS, Ferry G, Cohen SA, Gold BD, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005; 11: 442–6.
    Direct Link:
  • 15
    Bermejo F, Lopez San Roman A, Algaba A, van Domselaar M, Carneros JA, Rivero M, et al. Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab. Gastroenterol Hepatol 2008; 31: 629–32.
  • 16
    Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17: 75–84.
    Direct Link:
  • 17
    Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther 2006; 24: 851–88.
    Direct Link:
  • 18
    Lequerre T, Vittecoq O, Klemmer N, Goeb V, Pouplin S, Menard JF, et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 2006; 33: 1307–14.
  • 19
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9.
  • 20
    Becker M, Rose CD, McIlvain-Simpson G. Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis [letter]. J Rheumatol 2004; 31: 2529–30.
  • 21
    Graham GG, Day RO, Milligan MK, Ziegler JB, Kettle AJ. Current concepts of the actions of paracetamol (acetaminophen) and NSAIDs. Inflammopharmacology 1999; 7: 255–63.
  • 22
    Rezende RM, Franca DS, Menezes GB, dos Reis WG, Bakhle YS, Francischi JN. Different mechanisms underlie the analgesic actions of paracetamol and dipyrone in a rat model of inflammatory pain. Br J Pharmacol 2008; 153: 760–8.
    Direct Link:
  • 23
    Chen C. Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem 2008; 15: 2173–91.
  • 24
    Antoni C, Kalden JR. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor α antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 1999; 17: S73–7.
  • 25
    Sany J, Kaiser MJ, Jorgensen C, Trape G. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1647–9.
  • 26
    Augustsson J, Eksborg S, Ernestam S, Gullstrom E, van Vollenhoven R. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1462–66.
  • 27
    Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, et al. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007; 34: 510–5.
View Full Article (HTML) Get PDF (72K)